

July 30, 2021

To,

**BSE Limited**

Corporate Relationship Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400 001

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

Scrip code: 512529

Symbol: SEQUENT

**Subject: Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended March 31, 2021.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



**Krunal Shah**  
**Company Secretary & Compliance Officer**



Encl.: As above

**SeQuent Scientific Limited**

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area,  
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

**Disclosure of related party transactions on consolidated basis**

*In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018*

**A List of related parties**

List of related parties with whom transactions have taken place during the period

**a) Key management personnel (KMP)**


Mr. Manish Gupta, Chief Executive Officer & Managing Director  
Mr. Sharat Narasapur, Joint Managing Director  
Mr. Tushar Mistry, Chief Financial Officer  
Mr. Krunal, Shah, Company Secretary  
Dr. Kamal K Sharma, Independent Director (w.e.f. 25 August 2020)  
Mr. Milind Sarwate, Independent Director (w.e.f. 25 August 2020)  
Mr. Gregory Andrews John, Non-Executive Director (w.e.f. 06 November 2020)  
Dr. Fabian Kausche, Non-Executive Director (w.e.f. 14 December 2020)  
Dr. Kausalya Santhanam, Independent Director

**b) Transaction with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries (refer note as below)**

Strides Emerging Markets Limited  
Tenshi Kaizen Private Limited  
Solara Active Pharma Sciences Limited  
Sequent Penems Private Limited

**Note:** Subsequent to change of control in the SeQuent Scientific Limited, the above entities have ceased to be related parties w.e.f. 17 August 2020 under the Companies Act, 2013. The Company has filed requisite application with the Stock Exchanges as prescribed under SEBI LODR regulations seeking re-classification of the erstwhile 'Promoter Group' into 'Public Category' and the Stock Exchange approval is still awaited.

*Ksshah*



# Continuation Sheet

## B Transactions during the period 01 October 2020 to 31 March 2021

Particulars	₹ in Million
<b>i) Transactions with KMP</b>	
<b>Managerial remuneration (*)</b>	
Mr. Manish Gupta	21.36
Mr. Sharat Narsapur	7.89
Mr. Tushar Mistry	6.73
Mr. Krunal Shah	0.79
<b>Directors sitting fees</b>	
Dr. Kamal K Sharma	1.20
Mr. Milind Sarwate	1.00
Mr. Gregory Andrews John	0.20
Dr. Fabian Kausche	0.10
Dr. Kausalya Santhanam	0.50
<b>ii) Transaction with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries</b>	
<b>Sale of materials/services</b>	
Strides Emerging Markets Limited	0.11
Solara Active Pharma Sciences Limited	14.31
Tenshi Kaizen Private Limited	0.25
<b>Purchase of materials</b>	
Solara Active Pharma Sciences Limited	109.08
<b>Commission expenses</b>	
Solara Active Pharma Sciences Limited	0.16
<b>Payment towards lease obligation and finance costs</b>	
Solara Active Pharma Sciences Limited	4.20
<b>Security deposit recovered from</b>	
Sequent Penems Private Limited	2.21
<b>iii) Balance as at 31 March 2021</b>	
<b>Trade Receivables / other current assets</b>	
Strides Emerging Markets Limited	0.12
Solara Active Pharma Sciences Limited	6.95
Tenshi Kaizen Private Limited	0.28
<b>Security deposit receivable</b>	
Solara Active Pharma Sciences Limited	4.20
Sequent Penems Private Limited	0.29
<b>Trade payables</b>	
Solara Active Pharma Sciences Limited	35.92

(\*) Expenses towards gratuity and compensated absences provisions are determined actuarially on an overall Group basis at the end of each year and accordingly have not been considered in the above information.

  
Tushar Mistry  
Chief Financial Officer

  
Krunal Shah  
Company Secretary



Place: Thane  
Date: 29 July 2021